SG11201407678YA - Somatostatin receptor agonist formulations - Google Patents

Somatostatin receptor agonist formulations

Info

Publication number
SG11201407678YA
SG11201407678YA SG11201407678YA SG11201407678YA SG11201407678YA SG 11201407678Y A SG11201407678Y A SG 11201407678YA SG 11201407678Y A SG11201407678Y A SG 11201407678YA SG 11201407678Y A SG11201407678Y A SG 11201407678YA SG 11201407678Y A SG11201407678Y A SG 11201407678YA
Authority
SG
Singapore
Prior art keywords
international
solvegatan
camurus
ideon
lund
Prior art date
Application number
SG11201407678YA
Inventor
Catalin Nistor
Markus Johnsson
Fredrik Tiberg
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49623188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407678Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/059917 external-priority patent/WO2012160213A1/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of SG11201407678YA publication Critical patent/SG11201407678YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 November 2013 (28.11.2013) WIPOIPCT (10) International Publication Number WO 2013/174978 A1 (51) International Patent Classification: A61K9/00 (2006.01) A61K 47/10 (2006.01) A61K 9/127 (2006.01) A61K 47/14 (2006.01) A61K38/00 (2006.01) A61K 47/24 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/060739 24 May 2013 (24.05.2013) English (30) Priority Data: PCT/EP2012/059917 25 May 2012 (25.05.2012) 61/730,613 28 November 2012 (28.11.2012) English EP US (71) Applicant: CAMURUS AB [SE/SE]; Ideon, Gamma 1, Solvegatan 41, SE-223 70 Lund (SE). (72) Inventors: NISTOR, Catalin; Camurus AB, Ideon, Gamma 1, Solvegatan 41, SE-223 70 Lund (SE). JOHNS- SON, Markus; Camurus AB, Ideon, Gamma 1, Solvegatan 41, SE-223 70 Lund (SE). TIBERG, Fredrik; Camurus AB, Ideon, Gamma 1, Solvegatan 41, SE-223 70 Lund (SE). (74) Agent: DEHNS; St Bride's House, 10 Salisbury Square, London EC4Y 8JD (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) 00 l> o\ •t l> i-H cn i-H o CJ o & (54) Title: SOMATOSTATIN RECEPTOR AGONIST FORMULATIONS (57) Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt.% of at least one diacyl glycerol; b) 20-54 wt.% of at least one phosphatidyl choline (PC); c) 5-15wt.% of at least one biocompatible, organic mono-alcohol - ic solvent; d) 1 to 20 wt.% polar solvent e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous flu­ id. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled adminis - tration devices and kits containing the formulations.
SG11201407678YA 2012-05-25 2013-05-24 Somatostatin receptor agonist formulations SG11201407678YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2012/059917 WO2012160213A1 (en) 2011-05-25 2012-05-25 Controlled release peptide formulations
US201261730613P 2012-11-28 2012-11-28
PCT/EP2013/060739 WO2013174978A1 (en) 2012-05-25 2013-05-24 Somatostatin receptor agonist formulations

Publications (1)

Publication Number Publication Date
SG11201407678YA true SG11201407678YA (en) 2014-12-30

Family

ID=49623188

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407678YA SG11201407678YA (en) 2012-05-25 2013-05-24 Somatostatin receptor agonist formulations

Country Status (23)

Country Link
US (2) US11672843B2 (en)
JP (1) JP6374380B2 (en)
KR (1) KR102139080B1 (en)
CN (1) CN104487050B (en)
AU (1) AU2013265210B2 (en)
BR (1) BR112014029425A2 (en)
CA (1) CA2874367C (en)
CL (1) CL2014003185A1 (en)
CO (1) CO7160067A2 (en)
DK (1) DK2861209T3 (en)
EA (1) EA035495B1 (en)
ES (1) ES2834318T3 (en)
HK (1) HK1207985A1 (en)
IL (1) IL235740A0 (en)
IN (1) IN2014DN09831A (en)
MA (1) MA37672A1 (en)
MX (1) MX350964B (en)
NZ (1) NZ702028A (en)
PE (1) PE20150195A1 (en)
PH (1) PH12014502614A1 (en)
SG (1) SG11201407678YA (en)
TN (1) TN2014000483A1 (en)
WO (1) WO2013174978A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2390331C2 (en) * 2004-06-04 2010-05-27 Камурус Аб Liquid drug reservoirs
US11433120B2 (en) * 2011-05-25 2022-09-06 Camurus Ab Controlled release peptide formulations
WO2018060213A1 (en) * 2016-09-27 2018-04-05 Camurus Ab Formulations containing a somatostatin receptor agonist
CN113018248B (en) * 2019-12-23 2022-07-22 南京清普生物科技有限公司 Sustained-release drug delivery system
CN114240934B (en) * 2022-02-21 2022-05-10 深圳大学 Image data analysis method and system based on acromegaly

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5340802A (en) 1989-06-30 1994-08-23 Abbott Laboratories Peptide analog type-B CCK receptor ligands
CA2535463A1 (en) 1989-07-07 1991-01-08 Novartis Ag Octreotide-pamoate and its use in sustained release formulations of water soluble peptides
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
WO1993006921A1 (en) 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
ATE182278T1 (en) 1991-10-04 1999-08-15 Gs Dev Ab PARTICLES, METHOD FOR PRODUCING THE PARTICLES AND THEIR USE
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
CA2186750C (en) 1994-03-30 2008-08-05 Jens Hansen Use of fatty acid esters as bioadhesive substances
SE518578C2 (en) 1994-06-15 2002-10-29 Gs Dev Ab Lipid-based composition
FR2725369B1 (en) 1994-10-07 1997-01-03 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION CONSISTING OF AN OIL IN WATER EMULSION BASED ON OIL CELLS PROVIDED WITH A LAMELLAR LIQUID CRYSTAL COATING
AU702030B2 (en) 1995-10-12 1999-02-11 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
JP2001524958A (en) 1997-04-17 2001-12-04 ジーエス ディベロップメント アクティエボラーグ A novel liquid crystal based bioadhesive drug delivery system
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US20040018241A1 (en) 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
BE1011899A6 (en) 1998-04-30 2000-02-01 Ucb Sa PHARMACEUTICAL USE gelling.
SI1140148T1 (en) 1998-12-22 2006-04-30 Lilly Co Eli Shelf-stable solution formulation of glucagon-like peptide-1
US6011067A (en) 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US20020153508A1 (en) 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
CA2451432A1 (en) 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
DK1412384T3 (en) 2001-06-28 2008-04-28 Novo Nordisk As Stable formulation of modified GLP-1
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
US7622118B2 (en) 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
ATE411101T1 (en) 2003-08-04 2008-10-15 Camurus Ab METHOD FOR LOADING AMPHIPHIL PARTICLES WITH ACTIVE SUBSTANCES
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
GB0322033D0 (en) 2003-09-19 2003-10-22 Camurus Ab Composition
DK1682091T3 (en) 2003-11-07 2017-05-15 Camurus Ab COMPOSITIONS OF LIPIDS AND CATIONIC PEPTIDES
WO2005063213A1 (en) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
DE602005025083D1 (en) 2004-01-23 2011-01-13 Camurus Ab
RU2390331C2 (en) 2004-06-04 2010-05-27 Камурус Аб Liquid drug reservoirs
CA2575906C (en) 2004-08-04 2014-04-15 Camurus Ab Compositions forming non-lamellar dispersions
ES2400034T3 (en) 2005-01-14 2013-04-05 Camurus Ab Topical bioadhesive formulations
CA2594710C (en) 2005-01-14 2011-01-25 Camurus Ab Topical bioadhesive formulations
DE602005026998D1 (en) 2005-01-14 2011-04-28 Camurus Ab SOMATOSTATIN-ANALOG FORMULATIONS
PL1843746T3 (en) * 2005-01-14 2011-09-30 Camurus Ab Somatostatin analogue formulations
KR101245022B1 (en) 2005-01-21 2013-03-19 카무러스 에이비 Pharmaceutical lipid compositions
DK1888031T3 (en) 2005-06-06 2013-02-18 Camurus Ab GLP-1 analog formulations
CA2629300C (en) 2005-11-17 2014-07-08 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
AR066677A1 (en) * 2007-05-24 2009-09-02 Novartis Ag FORMATION OF PASSIREOTIDE. PHARMACEUTICAL COMPOSITION FOR PROLONGED RELEASE. MICROPARTICLES.
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
PT2310042E (en) * 2008-07-08 2013-03-11 Novartis Ag Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
US11433120B2 (en) * 2011-05-25 2022-09-06 Camurus Ab Controlled release peptide formulations
CN104093399B (en) * 2011-12-05 2018-03-13 卡穆鲁斯公司 Robustness controlled release peptide formulations

Also Published As

Publication number Publication date
AU2013265210A1 (en) 2014-12-04
NZ702028A (en) 2016-07-29
TN2014000483A1 (en) 2016-03-30
CA2874367C (en) 2020-08-18
MX2014014379A (en) 2015-02-05
CL2014003185A1 (en) 2015-04-24
PE20150195A1 (en) 2015-02-27
US11672843B2 (en) 2023-06-13
EA035495B1 (en) 2020-06-25
ES2834318T3 (en) 2021-06-17
CN104487050B (en) 2019-08-20
HK1207985A1 (en) 2016-02-19
IN2014DN09831A (en) 2015-08-07
AU2013265210B2 (en) 2016-09-15
EA201491928A1 (en) 2015-09-30
MX350964B (en) 2017-09-27
WO2013174978A1 (en) 2013-11-28
KR20150016977A (en) 2015-02-13
CA2874367A1 (en) 2013-11-28
BR112014029425A2 (en) 2017-06-27
JP2015520762A (en) 2015-07-23
KR102139080B1 (en) 2020-07-29
US20150105332A1 (en) 2015-04-16
CN104487050A (en) 2015-04-01
DK2861209T3 (en) 2020-12-21
MA37672A1 (en) 2016-07-29
PH12014502614A1 (en) 2015-01-21
JP6374380B2 (en) 2018-08-15
CO7160067A2 (en) 2015-01-15
US20230372436A1 (en) 2023-11-23
IL235740A0 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201903331QA (en) Restimulation of cryopreserved tumor infiltrating lymphocytes
SG11201809132RA (en) Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407200TA (en) Liquid formulation
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201407747QA (en) A method and apparatus for facilitating the management of health and security
SG11201407397WA (en) Formulations and methods for vaginal delivery of antiprogestins
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201407678YA (en) Somatostatin receptor agonist formulations
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201808686VA (en) Synthesis of indazoles
SG11201407229UA (en) Substituted pyrazole compounds as lpar antagonists
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201906767XA (en) Estrogen receptor modulators
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea